

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	collagenase clostridium histolyticum
Brand Name	Xiaflex™
Dosage Form(s)	0.9 mg/ vial (lyophilized powder for injection)
Manufacturer	Actelion Pharmaceuticals Canada Inc.
Submission Type	New Submission
Use Reviewed	For the treatment of Dupuytren's contracture with a palpable cord
Common Drug Review (CDR)	Yes, CDR recommended: to Reimburse with clinical criteria and/or conditions . Visit the CDR website for more details: www.cadth.ca/media/cdr/complete/cdr_complete_Xiaflex_April-1-13.pdf
Drug Benefit Council (DBC) or Provincial Review (choose one)	The DBC met on June 10, 2013. DBC considered various inputs including: general inputs (e.g. CDR, CER and PER), input from a specialist and a general practitioner, and # patient-type inputs) DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened Xiaflex on June 10, 2013. The DBC advised that because collagenase clostridium histolyticum is similar to some of the other drugs used for the treatment of Dupuytren's contracture with a palpable cord, the Ministry may accept the CDEC's recommendation for collagenase clostridium histolyticum.
Drug Coverage Decision	Non-Benefit
Date	March 25, 2014
Reason(s)	Drug coverage decision is not consistent with the DBC recommendation. <ul style="list-style-type: none"> ○ DBC recommended that Xiaflex be listed with criteria, however the Ministry decided not list this drug because: <ul style="list-style-type: none"> ○ Drug was only effective in clinical trials compared to vehicle (no treatment). ○ Drug was not compared to surgical treatment options which are commonly used to treat Dupuytren's contracture, so it is unknown how effective drug is compared to surgical treatments. ○ Value for money with Xiaflex is uncertain because it is uncertain how this drug compares to surgical options.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.